PharmAust drug delivers ‘remarkable’ results in COVID-19 test

19/06/2020 - 06:45

Bookmark

Save articles for future reference.

ASX-listed PharmAust Limited has shown that the initial successful testing of its cancer fighting drug, Monepantel, against the COVID-19 virus may not have been a fluke, with new testing showing a “remarkable” 95% suppression rate in the infectivity of the SARS-CoV- 2 virus (COVID-19) in laboratory tests by both Monepantel and Monepantel sulfone. Testing was undertaken at Walter and Eliza Hall Institute of Medical Research in Melbourne.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options